08:24 AM EDT, 09/02/2025 (MT Newswires) -- Emergent BioSolutions ( EBS ) said Tuesday it received a $30 million contract modification to supply Cyfendus, a vaccine to combat anthrax, to the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority.

The company said the vaccine was approved by the US Food and Drug Administration in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis use in individuals 18 through 65 years of age when given with recommended antibacterial drugs.

Deliveries are expected to begin this year and are scheduled to be completed by March 2026.

Emergent BioSolutions ( EBS ) shares were up 0.9% in recent premarket activity.